UB Paderborn / Katalog / Suche / in CDI

40 InnovaTV 301/ENGOT-cx12/GOG-3057: tisotumab vedotin vs investigator’s choice chemo in second- or third-line recurrent or metastatic cervical cancer

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A1-A1

2021

Link zum Volltext

Verfügbarkeit prüfen

1109 Quality of life and sexual functioning after treatment for locally advanced cervical cancer – CCRT versus NACT-S

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A330-A330

2021

Link zum Volltext

Verfügbarkeit prüfen

1056 Live surgical broadcast and patient outcome – 10 years of experience from the international Charité MAYO conferences 2010–2019

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A191-A191

2021

Link zum Volltext

Verfügbarkeit prüfen

167 Safety and quality of life of first-line maintenance olaparib plus bevacizumab in older patients with advanced ovarian cancer in the PAOLA-1 trial

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A201-A202

2021

Link zum Volltext

Verfügbarkeit prüfen

185 ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo + adjuvant chemotherapy ± radiotherapy for high-risk endometrial cancer

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A79-A80

2021

Link zum Volltext

Verfügbarkeit prüfen

199 Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A12-A12

2021

Link zum Volltext

Verfügbarkeit prüfen

Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: Can the risk be reduced?

American journal of obstetrics and gynecology, 1999-09, Vol.181 (3), p.536-541

1999

Link zum Volltext

Verfügbarkeit prüfen

AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)

ANNALS OF ONCOLOGY, 2020, Vol.31, p.S617

2020

Link zum Volltext

Verfügbarkeit prüfen

The rationale of opportunistic bilateral salpingectomies (OBS) during benign gynaecological and obstetric surgery: a consensus text of the Flemish Society of Obstetrics and Gynaecology (VVOG)

Facts, views & vision in ObGyn, 2019-06, Vol.11 (2), p.177-187

2019

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer

Seminars in oncology, 2000-06, Vol.27 (3 Suppl 7), p.31

2000

Link zum Volltext

Verfügbarkeit prüfen

Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern

Cancer, 1996-10, Vol.78 (8), p.1740-1747

1996

Link zum Volltext

Verfügbarkeit prüfen

Predicting the clinical behavior of ovarian cancer from gene expression profiles

International journal of gynecological cancer, 2006-02, Vol.16 (S1), p.147-151

2006

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC gynaecological cancer cooperative group study

European journal of cancer (1990), 1999-09, Vol.35 (9), p.1331-1337

1999

Link zum Volltext

Verfügbarkeit prüfen

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse

American journal of obstetrics and gynecology, 1993-07, Vol.169 (1), p.40-52

1993

Link zum Volltext

Verfügbarkeit prüfen

Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles

Clinical cancer research, 2005-11, Vol.11 (21), p.7958-7959

2005

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer

Cancer, 1992-02, Vol.69 (3), p.741-749

1992

Link zum Volltext

Verfügbarkeit prüfen

Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer

European journal of cancer (1990), 1998-07, Vol.34 (8), p.1175-1180

1998

Link zum Volltext

Verfügbarkeit prüfen

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma

Journal of clinical pathology, 1994-10, Vol.47 (10), p.914-919

1994

Link zum Volltext

Verfügbarkeit prüfen

Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer

European journal of gynaecological oncology, 1998, Vol.19 (5), p.434

1998

Link zum Volltext

Verfügbarkeit prüfen

Exenterative surgery

Current opinion in obstetrics & gynecology, 1997-02, Vol.9 (1), p.25-28

Vergote, I B

1997

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of serum CA 125 levels in the monitoring of ovarian cancer

American journal of obstetrics and gynecology, 1987-07, Vol.157 (1), p.88-92

1987

Link zum Volltext

Verfügbarkeit prüfen

Bleomycin-ifosfamide- cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: A second look

Gynecologic oncology, 1992-08, Vol.46 (2), p.203-207

1992

Link zum Volltext

Verfügbarkeit prüfen

Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second‐look laparotomy

Cancer, 1993-04, Vol.71 (7), p.2250-2260

1993

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma

European journal of cancer (1990), 1995-10, Vol.31 (11), p.1778-1780

1995

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant treatment of ovarian carcinoma

Acta obstetricia et gynecologica Scandinavica, 1993-11, Vol.72 (8), p.682-684

Vergote, Ignace B.

1993

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

40 InnovaTV 301/ENGOT-cx12/GOG-3057: tisotumab vedotin vs investigator’s choice chemo in second- or third-line recurrent or metastatic cervical cancer

1109 Quality of life and sexual functioning after treatment for locally advanced cervical cancer – CCRT versus NACT-S

1056 Live surgical broadcast and patient outcome – 10 years of experience from the international Charité MAYO conferences 2010–2019

167 Safety and quality of life of first-line maintenance olaparib plus bevacizumab in older patients with advanced ovarian cancer in the PAOLA-1 trial

185 ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo + adjuvant chemotherapy ± radiotherapy for high-risk endometrial cancer

199 Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer

Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: Can the risk be reduced?

AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)

The rationale of opportunistic bilateral salpingectomies (OBS) during benign gynaecological and obstetric surgery: a consensus text of the Flemish Society of Obstetrics and Gynaecology (VVOG)

Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer

Clear cell carcinoma of the endometrium: Prognosis and metastatic pattern

Predicting the clinical behavior of ovarian cancer from gene expression profiles

Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC gynaecological cancer cooperative group study

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse

Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles

Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer

Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma

Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer

Exenterative surgery

Evaluation of serum CA 125 levels in the monitoring of ovarian cancer

Bleomycin-ifosfamide- cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: A second look

Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second‐look laparotomy

A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma

Adjuvant treatment of ovarian carcinoma

Suchergebnisse filtern